Cervical Cancer Diagnostic Market Analysis By Test Type (Pap Testing Or Cytology Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy) And Segment Forecasts To 2024
The global cervical cancer diagnostic market was valued at USD 7 billion in 2015 and is expected to reach a value of USD 12 billion by 2024, according to a new report by Grand View Research, Inc. The key driving factors include the rising prevalence of cervical cancer, evolving screening technology, and various programs that promote routine check up and screening. According to the data published by the WHO, in 2012, over 270,000 women died due to cervical cancer, majority of which were from the developing countries. It is one of the most common cancer type diagnosed in women. Some of the etiological factors are multiple sex partners, and changing lifestyle, such as drinking & smoking and increased stress levels.
Furthermore, favorable government initiatives and increasing number of awareness programs are further expected to promote the market growth in coming few years. The National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working towards promoting the necessity for early screening of cervical cancer amongst mid aged women.
There is an increasing demand for technologically advanced diagnostic procedures that facilitate the early intervention of the disease. The industry players are focused on developing innovative technological solutions for accurate and efficient results. Advancement in screening techniques, such as use of biomarkers, is gaining importance. The upsurge in technological developments is anticipated to further drive industry growth.
On account of increasing adoption of Pap test, the number of deaths due to cervical cancer has declined significantly in past few years. It helps detect precancerous lesions at an early state and, thus, reduces the number of cervical cancer cases. The American Cancer Society stated that the cervical cancer cases in last 40 years in the U.S. have declined by more than 50%. Initially, the Pap test screening was carried out every year which lead to further unnecessary procedures. However, the American Cancer Society now recommends that women in the age group of 21 to 29 should undergo Pap test every 3 years.
Further Key Findings from the Study Suggest:
In 2015, the Pap testing segment held majority of the market share of 49.6%. The segment’s large share can be attributed to the high efficiency of the tests in early diagnosis. Also, the increasing awareness about the impact of early diagnosis contributed to its growth.
In 2015, North America was the leading regional market with a revenue share of 48.3%. The U.S. is a key market in North America. Growing incidence of cervical cancer coupled with initiatives undertaken by government agencies in the form of awareness programs pertaining to the early screening of the disease are key factors for the country’s large market share.
Asia Pacific is expected to witness lucrative growth over the forecast period growing at a CAGR of 9.6%. The various steps undertaken by governments of developing countries such as India, China, Philippines, and other in order to improve healthcare infrastructure and to improve access to healthcare facilities are amongst key factors attributing to region’s high growth. Also, high prevalence of cancer in developing nations and increasing consumer awareness levels drive the growth
This market is presently dominated by a few key participants such as Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Abbott Laboratories, OncoHealth Corp, Hologic, Inc., QIAGEN, Quest Diagnostics, Inc and Guided Therapeutics, Inc. The key players focus specially on developing innovative solutions for diagnosis. For instance, F. Hoffmann-La Roche Ltd., in 2014, launched automated CINtec PLUS cytology test that efficiently detects the presence of precancerous cells.
Furthermore, favorable government initiatives and increasing number of awareness programs are further expected to promote the market growth in coming few years. The National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working towards promoting the necessity for early screening of cervical cancer amongst mid aged women.
There is an increasing demand for technologically advanced diagnostic procedures that facilitate the early intervention of the disease. The industry players are focused on developing innovative technological solutions for accurate and efficient results. Advancement in screening techniques, such as use of biomarkers, is gaining importance. The upsurge in technological developments is anticipated to further drive industry growth.
On account of increasing adoption of Pap test, the number of deaths due to cervical cancer has declined significantly in past few years. It helps detect precancerous lesions at an early state and, thus, reduces the number of cervical cancer cases. The American Cancer Society stated that the cervical cancer cases in last 40 years in the U.S. have declined by more than 50%. Initially, the Pap test screening was carried out every year which lead to further unnecessary procedures. However, the American Cancer Society now recommends that women in the age group of 21 to 29 should undergo Pap test every 3 years.
Further Key Findings from the Study Suggest:
In 2015, the Pap testing segment held majority of the market share of 49.6%. The segment’s large share can be attributed to the high efficiency of the tests in early diagnosis. Also, the increasing awareness about the impact of early diagnosis contributed to its growth.
In 2015, North America was the leading regional market with a revenue share of 48.3%. The U.S. is a key market in North America. Growing incidence of cervical cancer coupled with initiatives undertaken by government agencies in the form of awareness programs pertaining to the early screening of the disease are key factors for the country’s large market share.
Asia Pacific is expected to witness lucrative growth over the forecast period growing at a CAGR of 9.6%. The various steps undertaken by governments of developing countries such as India, China, Philippines, and other in order to improve healthcare infrastructure and to improve access to healthcare facilities are amongst key factors attributing to region’s high growth. Also, high prevalence of cancer in developing nations and increasing consumer awareness levels drive the growth
This market is presently dominated by a few key participants such as Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Abbott Laboratories, OncoHealth Corp, Hologic, Inc., QIAGEN, Quest Diagnostics, Inc and Guided Therapeutics, Inc. The key players focus specially on developing innovative solutions for diagnosis. For instance, F. Hoffmann-La Roche Ltd., in 2014, launched automated CINtec PLUS cytology test that efficiently detects the presence of precancerous cells.
CHAPTER 1 EXECUTIVE SUMMARY
CHAPTER 2 MARKET SNAPSHOT
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Growing incidence of cervical cancer in middle aged women
3.1.1.2 Increasing number of awareness programs for cervical cancer screening
3.1.1.3 Technological advancement
3.1.2 Market restraint analysis
3.1.2.1 Changes in regulatory guidelines for cervical cancer screening
3.2 Penetration & Growth Prospect Mapping
3.3 Cervical cancer diagnostic market – SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.4 Industry Analysis – Porter’s
CHAPTER 4 MARKET CATEGORIZATION 1: TEST TYPE ESTIMATES & TREND ANALYSIS
4.1 Cervical cancer diagnostic market: Test Type Movement Analysis
4.2 Pap Testing
4.2.1 Pap testing market estimates and forecasts, 2013 – 2024 (USD Billion)
4.3 HPV Testing
4.3.1 HPV testing estimates and forecasts, 2013 – 2024 (USD Billion)
4.4 Cervical Biopsies
4.4.1 Cervical biopsies market estimates and forecasts, 2013 – 2024 (USD Billion)
4.5 Cystoscopy
4.5.1 Cystoscopy market estimates and forecasts, 2013 – 2024 (USD Billion)
CHAPTER 5 MARKET CATEGORIZATION 2: REGIONAL ESTIMATES & TREND ANALYSIS
5.1 Cervical cancer diagnostic market Share by Region, 2013 & 2024
5.2 North America
5.2.1 North America cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024 (USD Billion)
5.2.3 U.S.
5.2.3.1 U.S. cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.2.4 Canada
5.2.4.1 Canada cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.3 Europe
5.3.1 Europe cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.3.2 Germany
5.3.2.1 Germany cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.3.3 UK
5.3.3.1 UK cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.4 Asia Pacific
5.4.1 Asia Pacific cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.4.2 Japan
5.4.2.1 Japan cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.4.3 China
5.4.3.1 China cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.5 Latin America
5.5.1 Latin America cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.5.2 Brazil
5.5.2.1 Brazil cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.5.3 Mexico
5.5.3.1 Mexico cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.6 MEA
5.6.1 MEA cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.6.2 South Africa
5.6.2.1 South Africa cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 Strategy Framework
6.2 Market Participation Categorization
6.3 Company Profiles
6.3.1 Abbott Molecular
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 Product benchmarking
6.3.1.4 Strategic initiatives
6.3.2 F. Hoffmann-La Roche Ltd
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 Product benchmarking
6.3.2.4 Strategic initiatives
6.3.3 QIAGEN
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 Product benchmarking
6.3.3.4 Strategic initiatives
6.3.4 Quest Diagnostics, Inc.
6.3.4.1 Company overview
6.3.4.2 Financial performance
6.3.4.3 Product benchmarking
6.3.4.4 Strategic initiatives
6.3.5 Hologic, Inc.
6.3.5.1 Company overview
6.3.5.2 Financial performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 Arbor Vita Corporation
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 Product benchmarking
6.3.6.4 Strategic initiatives
6.3.7 OncoHealth Corporation
6.3.7.1 Company overview
6.3.7.2 Financial performance
6.3.7.3 Product benchmarking
6.3.7.4 Strategic initiatives
6.3.8 Dell Guided Therapeutics, Inc.
6.3.8.1 Company overview
6.3.8.2 Financial performance
6.3.8.3 Product benchmarking
6.3.8.4 Strategic initiatives
6.3.9 CooperSurgical, Inc.
6.3.9.1 Company overview
6.3.9.2 Financial performance
6.3.9.3 Product benchmarking
6.3.9.4 Strategic initiatives
6.3.10 Becton, Dickinson and Company (BD)
6.3.10.1 Company overview
6.3.10.2 Financial performance
6.3.10.3 Product benchmarking
6.3.10.4 Strategic initiatives
CHAPTER 2 MARKET SNAPSHOT
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Growing incidence of cervical cancer in middle aged women
3.1.1.2 Increasing number of awareness programs for cervical cancer screening
3.1.1.3 Technological advancement
3.1.2 Market restraint analysis
3.1.2.1 Changes in regulatory guidelines for cervical cancer screening
3.2 Penetration & Growth Prospect Mapping
3.3 Cervical cancer diagnostic market – SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.4 Industry Analysis – Porter’s
CHAPTER 4 MARKET CATEGORIZATION 1: TEST TYPE ESTIMATES & TREND ANALYSIS
4.1 Cervical cancer diagnostic market: Test Type Movement Analysis
4.2 Pap Testing
4.2.1 Pap testing market estimates and forecasts, 2013 – 2024 (USD Billion)
4.3 HPV Testing
4.3.1 HPV testing estimates and forecasts, 2013 – 2024 (USD Billion)
4.4 Cervical Biopsies
4.4.1 Cervical biopsies market estimates and forecasts, 2013 – 2024 (USD Billion)
4.5 Cystoscopy
4.5.1 Cystoscopy market estimates and forecasts, 2013 – 2024 (USD Billion)
CHAPTER 5 MARKET CATEGORIZATION 2: REGIONAL ESTIMATES & TREND ANALYSIS
5.1 Cervical cancer diagnostic market Share by Region, 2013 & 2024
5.2 North America
5.2.1 North America cervical cancer diagnostic market estimates and forecasts, by test type 2013-2024 (USD Billion)
5.2.3 U.S.
5.2.3.1 U.S. cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.2.4 Canada
5.2.4.1 Canada cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.3 Europe
5.3.1 Europe cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.3.2 Germany
5.3.2.1 Germany cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.3.3 UK
5.3.3.1 UK cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.4 Asia Pacific
5.4.1 Asia Pacific cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.4.2 Japan
5.4.2.1 Japan cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.4.3 China
5.4.3.1 China cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.5 Latin America
5.5.1 Latin America cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.5.2 Brazil
5.5.2.1 Brazil cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.5.3 Mexico
5.5.3.1 Mexico cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.6 MEA
5.6.1 MEA cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
5.6.2 South Africa
5.6.2.1 South Africa cervical cancer diagnostic market estimates and forecasts, by test type 2013 – 2024 (USD Billion)
CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 Strategy Framework
6.2 Market Participation Categorization
6.3 Company Profiles
6.3.1 Abbott Molecular
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 Product benchmarking
6.3.1.4 Strategic initiatives
6.3.2 F. Hoffmann-La Roche Ltd
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 Product benchmarking
6.3.2.4 Strategic initiatives
6.3.3 QIAGEN
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 Product benchmarking
6.3.3.4 Strategic initiatives
6.3.4 Quest Diagnostics, Inc.
6.3.4.1 Company overview
6.3.4.2 Financial performance
6.3.4.3 Product benchmarking
6.3.4.4 Strategic initiatives
6.3.5 Hologic, Inc.
6.3.5.1 Company overview
6.3.5.2 Financial performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 Arbor Vita Corporation
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 Product benchmarking
6.3.6.4 Strategic initiatives
6.3.7 OncoHealth Corporation
6.3.7.1 Company overview
6.3.7.2 Financial performance
6.3.7.3 Product benchmarking
6.3.7.4 Strategic initiatives
6.3.8 Dell Guided Therapeutics, Inc.
6.3.8.1 Company overview
6.3.8.2 Financial performance
6.3.8.3 Product benchmarking
6.3.8.4 Strategic initiatives
6.3.9 CooperSurgical, Inc.
6.3.9.1 Company overview
6.3.9.2 Financial performance
6.3.9.3 Product benchmarking
6.3.9.4 Strategic initiatives
6.3.10 Becton, Dickinson and Company (BD)
6.3.10.1 Company overview
6.3.10.2 Financial performance
6.3.10.3 Product benchmarking
6.3.10.4 Strategic initiatives
LIST OF TABLES
TABLE 1 Global cervical cancer diagnostic market revenue, by test type, 2013 - 2024 (USD Billion)
TABLE 2 Global cervical cancer diagnostic market revenue, by region, 2013 - 2024 (USD Billion)
TABLE 3 North America cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 4 U.S. cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 5 Canada cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 6 Europe cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 7 Germany cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 8 UK cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 9 Asia Pacific cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 10 Japan cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 11 China cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 12 Latin America cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 13 Brazil cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 14 Mexico cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 15 MEA cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 16 South Africa cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 1 Global cervical cancer diagnostic market revenue, by test type, 2013 - 2024 (USD Billion)
TABLE 2 Global cervical cancer diagnostic market revenue, by region, 2013 - 2024 (USD Billion)
TABLE 3 North America cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 4 U.S. cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 5 Canada cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 6 Europe cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 7 Germany cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 8 UK cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 9 Asia Pacific cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 10 Japan cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 11 China cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 12 Latin America cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 13 Brazil cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 14 Mexico cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 15 MEA cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
TABLE 16 South Africa cervical cancer diagnostic market, by test type, 2013 - 2024 (USD Billion)
LIST OF FIGURES
FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT Analysis, by factor (Political & legal, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Cervical cancer diagnostic market: Test type outlook key takeaways
FIG. 10 Cervical cancer diagnostic market: Test type movement analysis
FIG. 11 Global Pap testing market estimates and forecasts, 2013 - 2024 (USD Billion)
FIG. 12 Global HPV testing market estimates and forecasts, 2013 - 2024 (USD Billion)
FIG. 13 Global colposcopy market estimates and forecasts, 2013 - 2024 (USD Billion)
FIG. 14 Global cervical biopsies market estimates and forecasts, 2013 - 2024 (USD Billion)
FIG. 15 Global cystoscopy market estimates and forecasts, 2013 - 2024 (USD Billion)
FIG. 16 Regional market place: Key takeaways
FIG. 17 Regional outlook, 2015 & 2024
FIG. 18 North America cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024(USD Billion)
FIG. 19 U.S. cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024(USD Billion)
FIG. 20 Canada cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 21 Europe cervical cancer diagnostic market estimates and forecasts,by test type, 2013 - 2024 (USD Billion)
FIG. 21 Germany cervical cancer diagnostic market estimates and forecasts,by test type, 2013 - 2024 (USD Billion)
FIG. 22 UK cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 23 Asia Pacific cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 24 Japan cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 25 China cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 26 Latin America cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 27 Brazil cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 28 Mexico cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 29 MEA cervical cancer diagnostic market estimates and forecasts, by test type 2013 -2024 (USD Billion)
FIG. 30 South Africa cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 31 Strategy framework
FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT Analysis, by factor (Political & legal, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Cervical cancer diagnostic market: Test type outlook key takeaways
FIG. 10 Cervical cancer diagnostic market: Test type movement analysis
FIG. 11 Global Pap testing market estimates and forecasts, 2013 - 2024 (USD Billion)
FIG. 12 Global HPV testing market estimates and forecasts, 2013 - 2024 (USD Billion)
FIG. 13 Global colposcopy market estimates and forecasts, 2013 - 2024 (USD Billion)
FIG. 14 Global cervical biopsies market estimates and forecasts, 2013 - 2024 (USD Billion)
FIG. 15 Global cystoscopy market estimates and forecasts, 2013 - 2024 (USD Billion)
FIG. 16 Regional market place: Key takeaways
FIG. 17 Regional outlook, 2015 & 2024
FIG. 18 North America cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024(USD Billion)
FIG. 19 U.S. cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024(USD Billion)
FIG. 20 Canada cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 21 Europe cervical cancer diagnostic market estimates and forecasts,by test type, 2013 - 2024 (USD Billion)
FIG. 21 Germany cervical cancer diagnostic market estimates and forecasts,by test type, 2013 - 2024 (USD Billion)
FIG. 22 UK cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 23 Asia Pacific cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 24 Japan cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 25 China cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 26 Latin America cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 27 Brazil cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 28 Mexico cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 29 MEA cervical cancer diagnostic market estimates and forecasts, by test type 2013 -2024 (USD Billion)
FIG. 30 South Africa cervical cancer diagnostic market estimates and forecasts, by test type, 2013 - 2024 (USD Billion)
FIG. 31 Strategy framework
